Sales and marketing. The increase in sales and marketing expenses for the quarter ended September 30, 2011, compared to the quarter ended September 30, 2010, was attributable to an increase in salaries resulting principally from the expansion of our sales force and an increase in professional fees in connection with our marketing and advertising initiatives.
Share-based compensation. The decrease in share-based compensation for the quarter ended September 30, 2011, compared to the same quarter in 2010, reflects a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decline in our stock price.
The provision for income taxes was $17.6 million for the quarter ended September 30, 2011, compared to $18.2 million for the same quarter in 2010. The estimated annual effective tax rates were approximately 28 percent and 36 percent as of September 30, 2011 and 2010, respectively. The decrease in the annual effective tax rate as of September 30, 2011 largely reflects reductions in annual estimates of non-deductible compensation and an increase in tax credits expected to be generated.
2011 Revenue GuidanceWe reaffirm our 2011 full-year revenue guidance for our three commercial products (Remodulin, Tyvaso and Adcirca), as we continue to expect related revenues to fall within a range of 5% above or below $750 million for 2011.
Note Regarding Discontinued OperationsResults for the three- and nine-month periods ended September 30, 2011 and September 30, 2010 do not include the results of Medicomp, Inc. (Medicomp), our former telemedicine subsidiary, which we sold during the fir
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved